However, different from the RNA-seq results, there was a relatively low PD-L1 positivity rate (17.5%, 11/63) in our TFE3-tRCC cohort as assessed via PD-L1 IHC staining. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.